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SHORT REPORT
Serological biomarkers in triage of FIT-positive subjects?
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ABSTRACT
FIT-based colorectal cancer screening has been implemented in many countries including Denmark,
where 916 colorectal cancer and 4468 high- or medium-risk adenoma patients were identified within
April–December 2014, among 16,806 subjects with a positive FIT test. Screening increases the overall
requirements for colonoscopy, which may challenge the current capacity. Some countries have
increased their initial FIT cut-off level in order to comply with lack of colonoscopy capacity. Many
patients with neoplasia will not be detected, however, by using increased FIT cut-off levels. The num-
ber of patients with neoplastic lesions missed by increased cut-off levels appears to be much higher
than expected. Therefore, tests that identify those patients missed by increased FIT cut-off levels must
be developed. Preliminary results of determination of one of several biomarker entities currently under
investigation show that nucleosome blood tests may be one option for identifying some of these
patients. Implementation of a triage test consisting of FIT, blood-based biomarkers and plus/minus col-
onoscopy is suggested to identify subjects with FIT levels between the initial and the increased cut-off
level that must be offered colonoscopy. In addition, triage may reduce the frequency of unnecessary
colonoscopies by 25%.
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Report
As with a number of European countries, Denmark has initi-
ated population screening for colorectal cancer (CRC) among
the average risk population of 50–74 years of age. The
Danish model is based on Fecal Immunochemical Testing
(FIT) using an out-reach procedure with subsequent offer of
colonoscopy to all subjects with a positive FIT result (cut-off:
100 ng/ml). Requests to screening were launched by March
2014, with invitations being sent to approximately a 25% of
the screen relevant population annually including all Danish
citizens with birth dates occurring during three different
months at Year 1, during three other months at Year 2, etc.
The entire screen relevant population is estimated to be
invited before the end of December 2017.
Reports are available for the year 2014; overall the screen-
ing has been an overwhelming success. In total 390,509 sub-
jects were invited in that period, the compliance rate was
64% and 16,806 subjects (6.8%) had a positive FIT result that
led to subsequent referral to colonoscopy that was com-
pleted within 14 days. Colonoscopy referral was accepted by
89% and led to detection of 916 patients with CRC, and 4418
with high-risk (HRA) or medium-risk (MRA) adenoma
(Table 1). The CRC stage [Union for International Cancer
Control (UICC)] distribution was: Stage I: 28% (12%), Stage II:
36% (35%), Stage III: 26% (34%) and Stage IV: 10% (19%)
(stage distribution among non-screen diagnosed patients).
It is well-recognised that CRC screening leads to substan-
tially increased numbers of colonoscopy referrals in addition
to those required for routine diagnostics and surveillance.
Calculations by the Danish CRC screening board estimated
that screening would require an additional 18,000 colonos-
copy procedures annually during the 4 years taken to offer a
first FIT screening of all screen relevant Danish citizens. To
meet the increased demand, some countries, including
Denmark, have launched training programmes for nurses to
perform some of the colonoscopy procedures, and the present
Danish colonoscopy capacity appears to meet demands. By
2018, however, the screening invitation interval will be
reduced from every fourth year to every second year which,
by current estimates, will require 34,500 colonoscopies
annually in addition to those required for routine diagnostics
and surveillance. This is likely to lead both to an immediate
challenge to the colonoscopy capacity through FIT-positive
referrals, as well as an increase in surveillance colonoscopy
procedures required for patients with HRA and MRA (Table 1).
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Insufficient colonoscopy capacity may be one of the fac-
tors that have led to increased cut-off levels used in FIT
screening in some European countries, including Sweden,
Scotland and the Netherlands. However, increased cut-off lev-
els may result in a number of CRC and HRA/MRA patients
not being detected. Consequently, the value of CRC screen-
ing may be jeopardised substantially, even if this is tempor-
ary. Thereby, the populations may develop a distrust of the
value of CRC screening.
We recently completed the accrual of Part 1 of the
Endoscopy III validation study on blood-based biomarkers for
early detection of neoplastic lesions, including CRC [1]. The
primary aim of the study, which followed the REMARK guide-
lines [2], was to collect blood samples and data from >8000
subjects screened positive with FIT; analyses of various bio-
markers can be used to develop and validate a blood test for
screening of CRC either as single testing or in combination
with FIT [1]. The final inclusion comprised blood samples,
demographic data, occult blood (FIT) concentration
(100 FIT <1000 ng/ml) and subsequent colonoscopy data
from 8415 subjects with a positive FIT result and in addition
blood samples and demographic data from 5118 subjects
with a negative FIT result [35< FIT <100 ng/ml (35 ng/ml is
the detection limit)]; subjects with negative FIT results did
not undergo colonoscopy. All included subjects were partici-
pants of the Danish screening programme. The files are pres-
ently audited on-site or by access to national databases,
including colonoscopy and pathology reports. The results of
the first 1977 of the 8415 included FIT-positive subjects are
finalised and presented with the findings at colonoscopy
grouped by FIT thresholds. Indeed, the 1977 subjects were
accrued in the same period as the reported data from the
Danish screening programme (2014). Table 2 shows the num-
ber and percentage of colonoscopies that could be avoided
in the study population by increasing the FIT cut-off levels.
Efforts to reduce the number of screen colonoscopies in
Denmark from 2018 may lead to similar considerations to
increase the FIT cut-off level as in other European countries. It
must be considered however, that although increased FIT cut-
off levels reduce the numbers of screen colonoscopies substan-
tially, such changes will lead to considerable number of dis-
eased subjects, who would not be detected by screening as
illustrated in Table 2. In the event that the future cut-off is
increased from 100 to 200 ng/ml, screen colonoscopies could
be reduced by 32.6% (Table 2), but 11 CRCs, 52 HRAs and 90
MRAs would not have been detected among the 644 FIT-
screened subjects. Therefore, tests to identify those subjects at
risk of having neoplastic bowel lesions, but not identified by
current screening programmes using increased FIT cut-off lev-
els, must be developed, validated and implemented. Such test
options may consider serological biomarkers including proteo-
mics, genomics, epigenomics, transcriptomics, metabolomics,
etc., which may be used as single markers or in various combi-
nations to improve the sensitivity of the testing. Ideally, a tri-
age concept may be developed and clinically validated in
studies, which also focus on cost-benefit issues, for implemen-
tation in future screening programmes. For instance, such pro-
grammes using FIT testing with a cut-off level at 200 ng/ml
may offer a blood test to subjects with FIT between 100 ng/ml
and the increased level (Table 2). Thereby, the subjects that
need a colonoscopy could be identified from those, who do
not need a colonoscopy.
At present, analyses of various cell-free, circulating nucleo-
somes and histone modifications, including 5-methylcytosine-
methylated DNA, histone variant H2AZ, histone 3 variant
H2AX, histone variant mH2A1.1 and total nucleosomes, have
been performed in serum samples from the 1977 subjects
with a positive FIT test [3,4]. Application of these results
would have identified a number of subjects in need of colon-
oscopy due to increased risk of having neoplastic lesions
(Table 2). The statistical model to differentiate between sub-
jects, who need and subjects, who do not need colonoscopy
is based on logistic regression using a threshold correspond-
ing to 75% sensitivity for those with FIT concentration
between 100 ng/ml and the increased level shown in Table 2.
These preliminary results show that inclusion of triage
(FIT/blood test/colonoscopy) could be advantageous com-
pared to increased, fixed FIT cut-off levels to reduce the
numbers of screen colonoscopies. The Screening Boards
should consider recommendation of an increase of the FIT
cut-off level for instance to 200 ng/ml; in addition, it may be
considered offering subjects with FIT levels 100 FIT
<200 ng/ml a subsequent blood test. Present calculations
show that the total number of unnecessary colonoscopies
could be reduced by 25% by FIT/blood test screening using
Table 2. Shows fixed, increased FIT cut-off levels and number (%) of unnecessary colonoscopies defined by the levels among 1977 subjects with positive FIT
result.
FIT cut-off level
(ng/ml)
Spared
co-lonoscopies,
n (%)
Missed CRC,
n (%)
Missed HRA,
n (%)
Missed MRA,
n (%)
Identified CRC,
n (%)a
Identified HRA,
n (%)a
Identified MRA,
n (%)a
200 644 (32) 11 (9) 52 (20) 90 (25) 5 (45) 15 (28) 41 (45)
250 868 (44) 27 (23) 78 (30) 122 (45) 10 (37) 21 (27) 50 (41)
300 1005 (51) 33 (28) 95 (36) 145 (41) 14 (42) 26 (27) 54 (37)
400 1193 (60) 43(36) 120 (46) 183 (52) 18 (42) 33 (27) 65 (35)
500 1311 (66) 47 (40) 142 (55) 204 (58) 19 (40) 44 (31) 70 (34)
1000 1977 (100) 118 (100) 260 (100) 350 (100) 52 (44) 92 (35) 123 (35)
Numbers (%) of neoplastic lesions missed at the various cut-off levels and numbers (%) of neoplastic lesions identified by analyses of serum nucleosomes.
aPercentage of the number missed by increased FIT cut-off levels.
Table 1. Present Danish criteria for histological diagnosis of the various aden-
oma categories.
HRA Size 20mm Lesions 5 Resected by
piece-meal
technique
MRA 10 size <20mm 3 lesions <5 High-grade
neoplasia
Villous elements
LRA Size <10mm Lesions <3 Low-grade
neoplasia
Tubular lesions
LRA: low-risk adenoma.
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the FIT cut-off level at 200 ng/ml. That calculation includes
the number of subjects with FIT result between 100 and
200 ng/ml minus those subjects recommended for colonos-
copy due to the result of the blood testing. This preliminary
and still not sufficient predictor would correctly identify 5
(45%) with CRC, 15 (28%) with HRA and 41 (45%) with MRA.
The next steps in further evaluating triage in FIT screening
will include analyses of all 13,533 Endoscopy III Part 1 sam-
ples, interpretation of the results to settle the optimal FIT
cut-off level, inclusion of additional biomarker entities such
as proteins, DNA methylations, miRNA, metabolomes, etc.
[1,5–12] in various combinations, focus on logistics including
considerations of on-site or regional analyses and the time-
frame between FIT result and blood collection, interpretation
of the analysis results at the end-user level, and in particular
cost/benefit issues. Indeed, based on the present, preliminary
results an on-line algorithm will be developed and applied
on results of the remaining samples. Such on-line tools may
be valuable in future screening performance and acceptabil-
ity. Finally, a clinically controlled study must be initiated to
validate the triage concept in detail.
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